arGEN-X and LEO Pharma sign deal to develop antibody-based treatments for skin conditions

Published: 21-May-2015
Research & Development

Dutch biotechnology company could potentially receive nearly €105m in payments


Dutch biotech arGEN-X and global Danish healthcare company LEO Pharma have formed an alliance in which they will jointly develop antibody-based drugs for the treatment of chronic inflammation underlying many skin conditions.

Under the terms of the agreement LEO Pharma receives exclusive access to an arGEN-X antibody currently in preclinical development for such skin conditions. arGEN-X also receives pre-IND payments of €4.5m, including an upfront payment and will also receive clinical, regulatory, and sales milestone payments potentially worth €100m, plus tiered royalties.

The companies will co-fund product development costs up to clinical trial application (CTA) filing. Additional terms and financial details were not disclosed.

Tim Van Hauwermeiren, Chief Executive of arGEN-X said: 'We see huge potential in this new partnership in harnessing the complementary expertise of both companies: arGEN-X’s advanced knowledge and capabilities in therapeutic antibody development and LEO Pharma’s global expertise in bringing products to market that meets the needs of dermatology patients.'

Thorsten Thormann, Senior Vice President, New Product Discovery at LEO Pharma, said the alliance 'marks our entry into the area of biotherapeutics for dermatology'.

  • Companies:
  • Leo Pharma
  • ArGEN-X
See more

You may also like

Research & Development

Steritas and argenx join forces to advance steroid-sparing therapeutic development

Read more
With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. Precise and efficient VARIO diaphragm pumps from Vacuubrand Advanced vacuum control for reproducible processes
  3. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  4. Bio-Courier: a new delivery technology to increase the global accessibility of RNA therapeutics Although lipid nanoparticles (LNPs) are a key delivery technology for nucleic acid therapeutics, their wider clinical translation is hindered by the recognised limitations of current manufacturing protocols
  5. Photocatalysed flow method accelerates synthesis of potent MC4R antagonist New automated continuous flow synthesis of spirocyclic tetrahydronaphthyridines for drug discovery

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Research & Development

Steritas and argenx join forces to advance steroid-sparing therapeutic development

With the help of Steritas' STOX Suite, argenx aims to develop antibody-based therapeutics for immune diseases, potentially allowing patients to move away from chronic steroid usage
Research & Development

arGEN-X awarded €1.5m grant from IWT in Flanders

To advance the application of NHance Fc modifications in therapeutic antibodies
Research & Development

Shire signs monoclonal antibody agreement with arGEN-X

Will make an upfront payment to arGEN-X of €15m
Research & Development

arGEN-X to collaborate with Bayer

To discover and develop therapeutic antibody candidates
Research & Development

LEO Pharma and University of Queensland enter skin cancer treatments collaboration

Agreement will cover areas of skin cancer in which LEO Pharma is already active
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Drug approvals: more numerous but niche

After many years of low approval rates, in 2012 more than 30 new drugs were approved by the European Medicines Agency. Although many of them were niche products, some were for diseases with large patient populations, such as diabetes and various forms of cancer
Research & Development

LEO Pharma unveils collaboration strategy for dermatology treatments

To form five long-term partnerships in four countries
Subscribe now